Jose Fernando Moura, PhD· @FernandoOnco · X·· 15 hours agoScore70
Body
The biggest breakthrough in extensive-stage SCLC in decade
21.1 vs 12.7 months median OS. HR 0.42.
DeLLphi-305 may have just rewritten the future of first-line maintenance in SCLC.
The question is how soon we can make it accessible to our patients.
#ESMO26 #SCLC #DeLLphi305
60 views · 1 like · 0 reposts · 0 replies
Conference abstracts
LBA3matched by Presidential Symposium I
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgSource: Jose Fernando Moura, PhD · x.com